Login / Signup

AI and computational chemistry-accelerated development of an alotaketal analogue with conventional PKC selectivity.

Jumpei MakiAsami OshimuraChihiro TsukanoRyo C YanagitaYutaka SaitoYasubumi SakakibaraKazuhiro Irie
Published in: Chemical communications (Cambridge, England) (2022)
The protein kinase C (PKC) family consists of ten isozymes and is a potential target for treating cancer, Alzheimer's disease, and HIV infection. Since known natural PKC agonists have little selectivity among the PKC isozymes, a new scaffold is needed to develop PKC ligands with remarkable isozyme selectivity. Taking advantage of machine-learning and computational chemistry approaches, we screened the PubChem database to select sesterterpenoids alotaketals as potential PKC ligands, then designed and synthesized alotaketal analogues with a different ring system and stereochemistry from the natural products. The analogue exhibited a one-order higher affinity for PKCα-C1A than for the PKCδ-C1B domain. Thus, this compound is expected to serve as the basis for developing PKC ligands with isozyme selectivity.
Keyphrases
  • protein kinase
  • machine learning
  • emergency department
  • mass spectrometry
  • deep learning
  • antiretroviral therapy
  • structural basis
  • molecular dynamics simulations
  • squamous cell
  • capillary electrophoresis
  • drug induced